Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 5/20 | 0.52 |
| ▸ | LGALS4 | P56470 | 4/20 | 0.52 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.49 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SYNJ2 | O15056 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12807943 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL1682156 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL1682180 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL9545439 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL12595600 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL24192986 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL14413230 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL19869143 | 1.00 | LGALS3 (0.52) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL7150482 | 0.93 | LGALS8 (0.53) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL8658236 | 0.93 | LGALS3 (0.46) | LGALS3LGALS4LGALS9LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8845999-B2 | Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-09-30 | — | — | US | disclosed |
| US-7906460-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER (US) | 2011-03-15 | — | — | US | disclosed |
| US-20100008856-A1 | TRACERS FOR MONITORING THE ACTIVITY OF SODIUM/GLUCOSE COTRANSPORTERS IN HEALTH AND DISEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2007-08-02 | — | — | US | disclosed |
| US-7122359-B2 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and “unnatural” UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-17 | — | — | US | disclosed |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-03-20 | — | — | US | disclosed |
| US-5474986-A | Galabiose derivatives modified at 3* and anomeric positions | SYMBICOM AKTIEBOLAG (SE) | 1995-12-12 | — | — | US | disclosed |
| EP-0428605-B1 | SYNTHETIC RECEPTOR ANALOGUES | SYMBICOM AB (SE) | 1994-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008856-A1 | TRACERS FOR MONITORING THE ACTIVITY OF SODIUM/GLUCOSE COTRANSPORTERS IN HEALTH AND DISEASE | SLC5A1, SLC5A2, SLC2A1 | LGALS3 336/4885LGALS4 356/4885LGALS9 417/4885 |
| US-20030055235-A1 | Active-site engineering of nucleotidylyltransferases and general enzymatic methods for the synthesis of natural and \"unnatural\" UDP- and TDP-nucleotide sugars | PNP, NUDT14, ENTPD5 | LGALS3 2760/4885LGALS4 2139/4885LGALS9 2952/4885 |
| US-20070178487-A1 | ACTIVE-SITE ENGINEERING OF NUCLEOTIDYLYLTRANSFERASES AND GENERAL ENZYMATIC METHODS FOR THE SYNTHESIS OF NATURAL AND \"UNNATURAL\" UDP- AND TDP-NUCLEOTIDE SUGARS | PNP, NUDT14, NUDT5 | LGALS3 2517/4885LGALS4 2034/4885LGALS9 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.